Previous close | 9.18 |
Open | 6.31 |
Bid | 8.60 |
Ask | 9.80 |
Strike | 200.00 |
Expiry date | 2026-01-16 |
Day's range | 6.08 - 9.18 |
Contract range | N/A |
Volume | |
Open interest | 1 |
The FDA grants orphan drug and rare pediatric disease designations to LBPH's lead pipeline drug for the treatment of Dravet Syndrome.
With this approval, JNJ's Rybrevant is now approved for a total of four indications in the United States.
Data from a late-stage study shows that co-administering GSK's RSV and Shingles vaccines together was as effective as giving each separately.